VNRX News & Events

VolitionRx announces a collaboration with Sysmex, a leader in global in vitro diagnostics, to optimize Volition's Nu.Q NETs H3.1 assay on the Sysmex platform.

VolitionRx announces that it has expanded its intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus. Ebola is a rare but severe illness in humans, with an average case fatality rate around 50%. The disease is characterized by a low white cell count, disseminated intravascular coagulation, immunosuppression and septic shock. Volition is looking to translate this technology into immediate field application. The company is actively inviting global health organizations, pharmaceutical developers, non-governmental organizations, and distribution partners to collaborate on field trials, manufacturing scale-up, and potential deployment of its LFT prototypes in outbreak zones.

Cameron Reynolds, President and Group Chief Executive Officer, said: "We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end. We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q Vet platform."